A patient on aripiprazole (Abilify Maintena) 400 mg intramuscular injection every 4 weeks missed the next dose by 6 weeks; should the injection schedule be continued or restarted?

Restart Treatment with Oral Supplementation

Since the patient missed their Abilify Maintena 400 mg dose by 6 weeks (10 weeks total since last injection), you must restart the initiation protocol—either give the injection immediately with 14 days of oral aripiprazole 10-20 mg daily, or use the 1-day initiation method with two 400 mg injections plus one dose of oral aripiprazole 20 mg. 111

Why Restart is Required

The FDA labeling is explicit and unambiguous about this scenario. For the fourth or subsequent doses of Abilify Maintena:

• If ≤6 weeks have elapsed: Give the injection as soon as possible and continue the regular schedule
• If >6 weeks have elapsed: Must restart with full initiation protocol 111

Your patient is at 10 weeks (4 weeks scheduled + 6 weeks late), which exceeds the 6-week threshold. Simply continuing would leave the patient with subtherapeutic aripiprazole levels, as pharmacokinetic modeling demonstrates that therapeutic concentrations (≥95 ng/mL) cannot be maintained beyond this window 2.

Two Restart Options

Option 1: 14-Day Initiation (Preferred for Most Patients)

• Give one IM injection of 400 mg today (deltoid or gluteal)
• Continue oral aripiprazole 10-20 mg daily for 14 consecutive days
• Resume monthly injections (no sooner than 26 days after this injection)

Option 2: 1-Day Initiation (Faster Alternative)

• Give two IM injections of 400 mg in different injection sites (both deltoid, both gluteal, or one of each—but NOT the same muscle)
• Give one dose of oral aripiprazole 20 mg on the same day
• Resume monthly injections after 4 weeks

Clinical Rationale

The 6-week cutoff exists because aripiprazole has a long half-life (75 hours for parent compound, 94 hours for active metabolite), but the extended-release depot formulation requires overlapping coverage during reinitiation to prevent relapse 1. Patients with minimum concentrations below 95 ng/mL have a 4.41-times higher hazard ratio for relapse 2. After 6 weeks without an injection, levels fall below this therapeutic threshold.

Common Pitfalls to Avoid

• Do not simply give the next injection without oral coverage—this creates a dangerous gap where the patient is unprotected and at high relapse risk
• Check for CYP2D6/3A4 interactions: If the patient is on strong CYP2D6 or CYP3A4 inhibitors for >14 days, reduce the restart dose to 300 mg 11
• Assess current clinical status: If the patient is already showing signs of decompensation after 10 weeks without medication, consider brief oral stabilization before restarting the LAI
• Document the reason for the missed dose: This informs whether additional adherence interventions (reminders, caregiver involvement, shorter injection intervals) are needed 3

The distinction between second/third doses (5-week threshold) versus fourth and subsequent doses (6-week threshold) reflects the accumulation kinetics of the depot formulation 11. Your patient is well past the fourth dose, so the 6-week rule applies.